Abstract CT136: NUC-7738, a novel ProTide transformation of 3′-deoxyadenosine, in patients with advanced solid tumors
Ruth Plummer(National Health Service), Sarah P. Blagden(Churchill Hospital), Stefan N. Symeonides(Edinburgh Cancer Research), Michelle Myers(Nucana (United Kingdom)), Farasat Kazmi(University of Oxford), Francesca Aroldi(Churchill Hospital), Noor Md Haris(Freeman Hospital), Tze-en Ding(Western General Hospital)
Cited by 2
Related Papers
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
|New England Journal of Medicine|2020|406